SUS5 Antibody
Description
Antibody Characteristics
SUSD5 antibodies are typically polyclonal, raised in rabbits or mice, and target specific regions of the protein. Key features include:
Key Points:
-
Epitopes: Most antibodies target the C-terminal region (e.g., AA 593–629), which may play a role in membrane localization .
-
Specificity: Affinity purification via protein A and peptide columns ensures minimal cross-reactivity .
-
Formats: Available unconjugated or conjugated to HRP, FITC, or biotin for enhanced detection .
Research Applications
SUSD5 antibodies enable diverse experimental approaches:
Western Blotting (WB)
-
Detects SUSD5 at ~68 kDa in human cell lysates . Optimal dilution ranges from 1:1,000 to 1:5,000 depending on the antibody .
Immunohistochemistry (IHC)
-
Localizes SUSD5 in formalin-fixed paraffin-embedded tissues, showing membranous staining . Dilutions of 1:10–1:50 are typical .
Enzyme Immunoassay (EIA)
Key Research Findings
While the functional role of SUSD5 is not fully characterized, antibodies have revealed:
-
Expression Profile: SUSD5 is ubiquitously expressed in human tissues, with heightened detection in immune cells and epithelial linings .
-
Structural Insights: The C-terminal region is critical for antibody binding, as truncation or glycosylation abolishes reactivity .
-
Technical Performance: Antibodies like ABIN955013 show no cross-reactivity with SUSD5 homologs in non-human primates, underscoring their specificity for human studies .
Considerations for Use
-
Storage: Store at 2–8°C short-term or –20°C long-term in aliquots to prevent freeze-thaw degradation .
-
Sodium Azide Warning: Some formulations contain 0.09% sodium azide, requiring careful handling .
-
Validation: Always include positive controls (e.g., SUSD5-transfected cell lysates) and validate via peptide blocking assays .
Product Specs
Constituents: 50% Glycerol, 0.01M Phosphate Buffered Saline (PBS), pH 7.4
Target Background
STRING: 3702.AT5G37180.1
Q&A
Here’s a structured collection of FAQs for researchers working with SUS5 Antibody, synthesized from peer-reviewed methodologies and experimental design principles:
Advanced Research Questions
How to resolve discrepancies in SUS5 Antibody performance across experimental platforms?
What engineering strategies improve SUS5 Antibody manufacturability for therapeutic applications?
-
Framework optimization: Humanize SUS5 using germline frameworks with high expression (e.g., VH3-23/VK1-39) to reduce aggregation .
-
Affinity maturation: Employ phage display to balance binding strength (KD) and off-rate while avoiding over-engagement risks (e.g., cytokine release syndrome) .
How to design a robust SUS5 Antibody validation workflow for translational studies?
-
Pre-analytical phase: Standardize tissue handling (fixation time, pH) to prevent epitope masking .
-
Analytical phase:
-
Post-analytical phase: Benchmark against clinical outcomes (e.g., survival data) using Cox regression models .
Data Contradiction Analysis
Interpreting conflicting SUS5 expression data in public datasets
-
Scenario: SUS5 reported as both oncogenic and tumor-suppressive in different studies.
-
Resolution:
